Gene Therapy Setback: REGENXBIO’s RGX-121 Faces Regulatory Hurdles in Ultra-Rare Disease Treatment
- March 11, 2026
Serina Therapeutics Begins First-in-Patient Dosing in Phase 1b Trial of SER‑252 for Advanced Parkinson’s Disease
New Gene Editing Program Aims to Address Root Cause of PKU
From Psychiatric Bind to Clinical Solution: The VMAT2 Revolution in Treating Tardive Dyskinesia
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
This is TODAY- March 11th from @TripleNegativeBreastCancerFoundationJoin us March 11 at 1:00 PM ET for a ctDNA Testing Zoom Workshop with Dr. Dan Stover of Ohio State University Comprehensive Cancer Center. 🧬
Learn what circulating tumor DNA (ctDNA) is, how testing is used today, and what’s ahead. Stay for a live Q&A and gain valuable insights into the future of cancer care. Save your spot and register via the link!
#TNBCAwarenessMonth #CancerResearch #ctDNA
Gene Therapy Setback: REGENXBIO's RGX-121 Faces Regulatory Hurdles in Ultra-Rare Disease Treatment bit.ly/4b12esi Read now at PatientWorthy.com
#PatientWorthy #MPSII #HunterSyndrome #regenxbio #RGX-121
